Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

UroGen Pharma Ltd. Director's Dealing 2019

Jan 10, 2019

32312_dirs_2019-01-10_05826247-901e-4c11-8f0f-346620d9accb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-01-01

Reporting Person: Belldegrun Arie (Director)

Holdings (Non-Derivative)

Security Shares Ownership
Ordinary Shares 84211 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $5.00 2022-09-01 Ordinary Shares (3241) Direct
Stock Option (right to buy) $4.02 2019-10-14 Ordinary Shares (128000) Direct
Stock Option (right to buy) $5.00 2021-07-27 Ordinary Shares (3241) Direct
Stock Option (right to buy) $5.00 2022-10-07 Ordinary Shares (160000) Direct
Stock Option (right to buy) $43.67 2028-01-10 Ordinary Shares (20000) Direct
Stock Option (right to buy) $59.23 2028-06-04 Ordinary Shares (10000) Direct

Footnotes

F1: Fully vested.

F2: 25% of the shares underlying the stock option vested on each of October 13, 2012, October 13, 2013, October 13, 2014 and October 13, 2015.

F3: 25% of the shares underlying the stock option vested on each of October 7, 2016, October 7, 2017 and October 7, 2018 and the remaining 25% of the shares will vest on October 7, 2019.

F4: 25% of the shares underlying the stock option vested on each of April 10, 2018, July 10, 2018 and October 10, 2018 and the remaining 25% of the shares will vest on January 10, 2019.

F5: 25% of the shares underlying the stock option vested on each of September 4, 2018 and December 4, 2018 and the remaining shares will vest 25% on each of March 4, 2019 and June 4, 2019.